COMP360 Psilocybin in Chronic Suicidal Ideation: Reported MSSI Outcomes
More on this topicExpert Reels6
Twenty adults with chronic suicidal ideation. One 25 mg dose. MSSI scores fell from 18 to 4 by week three.
A two-speaker cut covering the design of an open-label COMP360 psilocybin trial in chronic suicidal ideation and the reported MSSI change and effect sizes at weeks 1, 3 and 12.
What the reel says
- Open-label, single-arm, 12-week trial of 20 adults with chronic suicidal ideation in the context of major depressive disorder, averaging five prior failed antidepressant trials.
- At the week 3 primary endpoint, MSSI scores fell roughly 14 points, from about 18 at baseline to about 4, a Cohen's d near 1.7.
- The largest effect was at week 1 (d of about 2.1), and the improvement was durable, still at d of 1.5 at week 12.
Distribution
Cut for
- X
Source
Two-speaker data reel produced from the COMP360 open-label trial results.
Suggested caption
A single 25 mg dose of COMP360 psilocybin in 20 adults with chronic suicidal ideation and major depressive disorder. MSSI scores fell by about 14 points at the week 3 primary endpoint, a Cohen's d near 1.7, with a 1.5 effect size still holding at week 12. Open-label, single-arm, and small, but the magnitude is hard to ignore.
Reel transcript 3 segments
-
Scott Aaronson
This was an open-label, single-arm, 12-week trial of 20 adults with chronic suicidal ideation in the context of major depressive disorder. Twelve men, eight women, mean age in the mid thirties. Participants had failed an average of five prior antidepressant trials. Each then received a single twenty-five milligram dose of COMP360 psilocybin.
-
Andrew van der Vaart
Week three was the primary endpoint, and at that time we saw the MSSI scores dropped by an average of about fourteen points. An eighteen on this suicidal severity scale at
-
baseline and about a four at week three. So this is a very large effect size. The Cohen's d, about 1.7, meaning almost two standard deviations reduced from baseline suicidal ideation. Week one was actually the largest effect size at around 2.1 standard deviations Cohen's d, and that improvement was durable. Week twelve, the overall end of the study, we still had a 1.5 effect size, substantial reduction in suicidal ideation.